Real‐World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)‐Mutant Metastatic Non‐Small Cell Lung Cancer, From a US‐Based Clinico‐Genomic Database
ABSTRACT Objectives Targeted therapies have been shown to improve outcomes in metastatic non‐small cell lung cancer (mNSCLC) with driver mutations. We evaluated the real‐world prevalence of human epidermal growth factor receptor 2 (HER2; ERBB2) tumor gene mutations among patients with mNSCLC and des...
Saved in:
Main Authors: | Sarah Waliany, Misako Nagasaka, Leah Park, Clara Lam, Zoe Jiang, Feng Lin, Joel W. Neal |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-12-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.70272 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report
by: Oliver Illini, et al.
Published: (2024-01-01) -
CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma
by: Laura M. Moser, et al.
Published: (2025-02-01) -
Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy
by: Yan Zhang, et al.
Published: (2025-12-01) -
Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan
by: Ünal Metin Tokat, et al.
Published: (2025-01-01) -
Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
by: Satomi Watanabe, et al.
Published: (2019-03-01)